ProUroCare buys up imaging patents:
This article was originally published in Clinica
In a bid to broaden its IP portfolio, ProUroCare Medical, a developer of mechanical imaging technology for detecting prostate disease, has bought a range of patents relating to prostate and breast imaging technologies from Profile. Minneapolis, Minnesota-based ProUroCare had originally licensed the patents from Profile to develop its ProUroScan prostate imaging system. By owning the patents outright, ProUroCare can pursue additional potential applications in the field of soft tissue imaging. The deal cost $300,000 - half was paid with $150,000 cash and the half was financed under a secured promissory note.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.